JP2021517135A5 - - Google Patents
Info
- Publication number
- JP2021517135A5 JP2021517135A5 JP2020547097A JP2020547097A JP2021517135A5 JP 2021517135 A5 JP2021517135 A5 JP 2021517135A5 JP 2020547097 A JP2020547097 A JP 2020547097A JP 2020547097 A JP2020547097 A JP 2020547097A JP 2021517135 A5 JP2021517135 A5 JP 2021517135A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- ror
- antagonist
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025003271A JP2025063134A (ja) | 2018-03-09 | 2025-01-09 | 化学療法抵抗性がんの組合せ処置 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862641035P | 2018-03-09 | 2018-03-09 | |
| US62/641,035 | 2018-03-09 | ||
| PCT/US2019/021694 WO2019173843A1 (en) | 2018-03-09 | 2019-03-11 | Combination treatment of chemoresistant cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025003271A Division JP2025063134A (ja) | 2018-03-09 | 2025-01-09 | 化学療法抵抗性がんの組合せ処置 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021517135A JP2021517135A (ja) | 2021-07-15 |
| JP2021517135A5 true JP2021517135A5 (https=) | 2022-03-18 |
Family
ID=67846369
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020547097A Pending JP2021517135A (ja) | 2018-03-09 | 2019-03-11 | 化学療法抵抗性がんの組合せ処置 |
| JP2025003271A Pending JP2025063134A (ja) | 2018-03-09 | 2025-01-09 | 化学療法抵抗性がんの組合せ処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025003271A Pending JP2025063134A (ja) | 2018-03-09 | 2025-01-09 | 化学療法抵抗性がんの組合せ処置 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11883492B2 (https=) |
| EP (1) | EP3762428A4 (https=) |
| JP (2) | JP2021517135A (https=) |
| CN (1) | CN112262157A (https=) |
| AU (1) | AU2019231321B2 (https=) |
| WO (1) | WO2019173843A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121471361A (zh) | 2022-03-09 | 2026-02-06 | 杭州中美华东制药有限公司 | 一种靶向ror1的结合分子及其应用 |
| CN120865418B (zh) * | 2025-09-28 | 2025-12-30 | 成都微芯新域生物技术有限公司 | 抗ror1抗体及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2361085T4 (en) * | 2008-11-22 | 2018-10-08 | Hoffmann La Roche | USE OF ANTI-VEGF ANTIBODY IN COMBINATION WITH CHEMOTHERY TO TREAT CANCER CANCER |
| JP2013529203A (ja) * | 2010-05-14 | 2013-07-18 | ジェネンテック， インコーポレイテッド | 治療方法 |
| EP3604339B1 (en) * | 2011-01-14 | 2021-03-10 | The Regents Of The University Of California | Therapeutic antibodies against ror-1 protein and methods for use of same |
| ES2702315T3 (es) | 2012-08-24 | 2019-02-28 | Univ California | Anticuerpos y vacunas para su uso en tratar cánceres ROR1 e inhibir metástasis |
| RU2689977C2 (ru) * | 2012-12-04 | 2019-05-30 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Применение эрибулина для лечения рака молочной железы |
| WO2016187220A2 (en) * | 2015-05-18 | 2016-11-24 | Five Prime Therapeutics, Inc. | Anti-ror1 antibodies |
| TWI767915B (zh) | 2016-06-27 | 2022-06-21 | 加州大學董事會 | Ror-1與btk拮抗劑的組合 |
-
2019
- 2019-03-11 JP JP2020547097A patent/JP2021517135A/ja active Pending
- 2019-03-11 CN CN201980031078.0A patent/CN112262157A/zh active Pending
- 2019-03-11 WO PCT/US2019/021694 patent/WO2019173843A1/en not_active Ceased
- 2019-03-11 US US16/979,469 patent/US11883492B2/en active Active
- 2019-03-11 EP EP19764748.0A patent/EP3762428A4/en active Pending
- 2019-03-11 AU AU2019231321A patent/AU2019231321B2/en active Active
-
2025
- 2025-01-09 JP JP2025003271A patent/JP2025063134A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Doebele et al. | A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer | |
| Yamaguchi et al. | Phase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancer | |
| Ohtsu | Chemotherapy for metastatic gastric cancer: past, present, and future | |
| TW202034959A (zh) | 抗體-藥物結合物與parp抑制劑之組合 | |
| RU2018146886A (ru) | Пути терапевтического применения ингибитора c-raf | |
| JP2013540694A (ja) | Ｈｅｒ３結合剤の前立腺治療における使用 | |
| JP2022511394A5 (https=) | ||
| JP6425653B2 (ja) | 抗腫瘍剤及び抗腫瘍効果増強剤 | |
| IL299099B1 (en) | Combinations of cancer treatments | |
| FI3464380T3 (fi) | Gp100-spesifisen tcr-anti-cd3 scfv-fuusioproteiinin annosteluohjelma | |
| JP2024533067A5 (https=) | ||
| JP2025063134A5 (https=) | ||
| US12053530B2 (en) | Plectin-1 binding antibodies and uses thereof | |
| JP2021517135A5 (https=) | ||
| JP2024527974A5 (https=) | ||
| RU2657604C2 (ru) | Противоопухолевый агент, включающий гидрат гидрохлорида иринотекана | |
| CN101175495B (zh) | 抗癌化合物的组合 | |
| KR20200105825A (ko) | 삼중 음성 유방암의 치료를 위한 ｐｄ－１ 항체 및 아파티닙의 조합 치료의 용도 | |
| JP2024511977A5 (https=) | ||
| RU2774721C2 (ru) | Применение комбинированного лечения на основе антитела к PD-1 и апатиниба для лечения трижды негативного рака молочной железы | |
| KR20250004821A (ko) | 항체-약물 접합체와 ezh1 및/또는 ezh2 억제제의 조합 | |
| RU2021133713A (ru) | Adc для лечения сопутствующе с или после доцетаксела | |
| RU2024104719A (ru) | Фармацевтическая композиция для лечения мелкоклеточного рака легкого | |
| Glass et al. | ANGI-02. INHIBITION OF APLN-APLNR SIGNALLING BLOCKS TUMOUR ANGIOGENESIS AND ATTENUATES INVASIVE GLIOBLASTOMA GROWTH | |
| Otani et al. | ANGI-01. FIBROBLAST GROWTH FACTOR 13 REGULATES GLIOMA CELL INVASION |